Coexisting subclonal mutations in patients with fusion-present colorectal cancer implicate fusions as a previously unreported, novel mechanism of resistance to anti–epidermal growth factor receptor therapies in patients with metastatic colorectal cancer. This evidence concerns the gene EGFR and metastatic colorectal cancer.